What triggered the 50% premarket surge in AtaiBeckley's stock?

AtaiBeckley's shares soared 50% premarket on Thursday after Bloomberg News reported that Eli Lilly was in talks to acquire the psychedelic drug developer as soon as that week, citing people familiar with the matter.

What is AtaiBeckley's lead candidate and therapeutic focus?

AtaiBeckley focuses on psychedelic-based treatments for mental health conditions and is developing BPL-003, an intranasal formulation of 5-MeO-DMT for treatment-resistant depression.

AtaiBeckley Surges After Report Lilly Poised to Buy Psychedelic Drug Developer

Jul 16, 2026

AtaiBeckley shares surged 50% premarket following reports that Eli Lilly is negotiating to acquire the psychedelic drug developer in a deal potentially exceeding $2 billion. The potential acquisition comes amid a broader industry rally driven by regulatory changes and investor interest in mental health treatments.

reuters

2026-02-03

Feb. 3 Business Watch: Catalysis start-ups raise money; Lilly strikes deals with 2 biotech firms

2026-03-31

Eli Lilly to Acquire Narcolepsy Drug Developer for $6.3 Billion

2026-04-29

Eli Lilly Investors Eager for Foundayo Insight After Early Launch Data

2026-04-30

Lilly lifts profit forecast as surging demand for weight-loss drugs offsets pricing pressure

2026-04-30

US Premarket Movers for April 30, 2026